Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.39 |
| ▸ | BRS3 | P32247 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29457486 | 0.82 | CYP2A6 (0.44) | CYP2A6CCR1CCR8GRM5IRAK4 | |
| SCHEMBL13659740 | 0.82 | ASIC3 (0.49) | IRAK4BRS3TGFBR1 | |
| SCHEMBL13728687 | 0.82 | MAPT (0.45) | CYP2A6TGFBR1 | |
| SCHEMBL30146674 | 0.80 | CYP2A6 (0.65) | CYP2A6CCR1CCR8GRM5METAP2 | |
| SCHEMBL3421947 | 0.80 | CYP2A6 (0.65) | CYP2A6CCR1CCR8GRM5METAP2 | |
| SCHEMBL29310630 | 0.80 | BTK (0.42) | TGFBR1 | |
| SCHEMBL13728929 | 0.78 | IDH1 (0.46) | TGFBR1 | |
| SCHEMBL13729151 | 0.78 | CTSS (0.46) | IRAK4BRS3TGFBR1 | |
| SCHEMBL13051887 | 0.77 | CCR1 (0.59) | CYP2A6CCR1CCR8GRM5METAP2 | |
| SCHEMBL24673834 | 0.76 | CYP2A6 (0.54) | CYP2A6CCR1CCR8GRM5METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203705-A1 | Spiro Compounds As NPY Y5 Receptor Antagonists | NPY4R, NPY1R, NPY5R | CYP2A6 1366/4885CCR1 271/4885CCR8 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.